32 related articles for article (PubMed ID: 1289359)
1. The cost-effectiveness of empirical antibiotic treatments for high-risk febrile neutropenic patients: A decision analytic model.
Tori K; Tansarli GS; Parente DM; Kalligeros M; Ziakas PD; Mylonakis E
Medicine (Baltimore); 2020 May; 99(20):e20022. PubMed ID: 32443305
[TBL] [Abstract][Full Text] [Related]
2. The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients.
Satlin MJ; Soave R; Racanelli AC; Shore TB; van Besien K; Jenkins SG; Walsh TJ
Leuk Lymphoma; 2014 Dec; 55(12):2858-65. PubMed ID: 24559288
[TBL] [Abstract][Full Text] [Related]
3. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia.
Paul M; Dickstein Y; Schlesinger A; Grozinsky-Glasberg S; Soares-Weiser K; Leibovici L
Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD003038. PubMed ID: 23813455
[TBL] [Abstract][Full Text] [Related]
4. Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects.
Zhanel GG; Simor AE; Vercaigne L; Mandell L;
Can J Infect Dis; 1998 Jul; 9(4):215-28. PubMed ID: 22346545
[TBL] [Abstract][Full Text] [Related]
5. Low-dose beta-lactam plus amikacin in febrile neutropenia: cefepime vs. piperacillin/tazobactam, a randomized trial.
Gómez L; Estrada C; Gómez I; Márquez M; Estany C; Martí JM; Bastús R; Cirera L; Quintana S; Garau J
Eur J Clin Microbiol Infect Dis; 2010 Apr; 29(4):417-27. PubMed ID: 20195673
[TBL] [Abstract][Full Text] [Related]
6. Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia.
Jimeno A; Arcediano A; Bazares S; Amador ML; González-Cortijo L; Ciruelos E; Robles L; Castellano D; Paz-Ares L; Lumbreras C; Hornedo J; Cortés-Funes H
Clin Transl Oncol; 2006 Dec; 8(12):889-95. PubMed ID: 17169762
[TBL] [Abstract][Full Text] [Related]
7. Piperacillin-tazobactam and netilmicin as a safe and efficacious empirical treatment of febrile neutropenic children.
Le Guyader N; Auvrignon A; Vu-Thien H; Portier E; Tabone MD; Leverger G
Support Care Cancer; 2004 Oct; 12(10):720-4. PubMed ID: 15138864
[TBL] [Abstract][Full Text] [Related]
8. Management of febrile neutropenia in low risk cancer patients.
Oppenheim BA; Anderson H
Thorax; 2000 Aug; 55 Suppl 1(Suppl 1):S63-9. PubMed ID: 10943642
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness of ceftazidime or imipenem/cilastatin versus ceftriaxone + aminoglycoside in the treatment of febrile episodes in neutropenic cancer patients in Germany.
Dietrich ES; Patz E; Frank U; Daschner FD
Infection; 1999; 27(1):23-7. PubMed ID: 10027102
[TBL] [Abstract][Full Text] [Related]
10. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.
Balfour JA; Bryson HM; Brogden RN
Drugs; 1996 Jan; 51(1):99-136. PubMed ID: 8741235
[TBL] [Abstract][Full Text] [Related]
11. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.
Davis R; Markham A; Balfour JA
Drugs; 1996 Jun; 51(6):1019-74. PubMed ID: 8736621
[TBL] [Abstract][Full Text] [Related]
12. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program.
Cometta A; Calandra T; Gaya H; Zinner SH; de Bock R; Del Favero A; Bucaneve G; Crokaert F; Kern WV; Klastersky J; Langenaeken I; Micozzi A; Padmos A; Paesmans M; Viscoli C; Glauser MP
Antimicrob Agents Chemother; 1996 May; 40(5):1108-15. PubMed ID: 8723449
[TBL] [Abstract][Full Text] [Related]
13. Piperacillin/tazobactam plus gentamicin as empirical therapy for febrile neutropenic patients with haematological malignancy.
Kelsey SM; Weinhardt B; Pocock CE; Shaw E; Newland AC
J Chemother; 1992 Oct; 4(5):281-5. PubMed ID: 1336043
[TBL] [Abstract][Full Text] [Related]
14. Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial.
Peacock JE; Herrington DA; Wade JC; Lazarus HM; Reed MD; Sinclair JW; Haverstock DC; Kowalsky SF; Hurd DD; Cushing DA; Harman CP; Donowitz GR
Ann Intern Med; 2002 Jul; 137(2):77-87. PubMed ID: 12118962
[TBL] [Abstract][Full Text] [Related]
15. [Comparative study of piperacillin/tazobactam versus imipenem/cilastatin in febrile neutropenia (1994-1996)].
Figuera A ; Rivero N; Pajuelo F; Font P; Leyra F; de La Cámara R; Arranz R; María Fernández Rañada J
Med Clin (Barc); 2001 May; 116(16):610-1. PubMed ID: 11412645
[TBL] [Abstract][Full Text] [Related]
16. Use of imipenem as empirical treatment of febrile neutropenia.
Klastersky JA
Int J Antimicrob Agents; 2003 May; 21(5):393-402. PubMed ID: 12727070
[TBL] [Abstract][Full Text] [Related]
17. Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.
Young M; Plosker GL
Pharmacoeconomics; 2001; 19(11):1135-75. PubMed ID: 11735679
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies.
Leyland MJ; Bayston KF; Cohen J; Warren R; Newland AC; Bint AJ; Cefai C; White DG; Murray SA; Bareford D
J Antimicrob Chemother; 1992 Dec; 30(6):843-54. PubMed ID: 1289359
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
